{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:07:16Z","timestamp":1791720436979,"version":"4.3.4"},"reference-count":29,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"E-Da Hospital","award":["EDAD2202"],"award-info":[{"award-number":["EDAD2202"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>The risk of fractures is higher in patients with autoimmune diseases, but it is not clear whether the use of immunosuppressive agents can further increase this risk. To investigate this issue, a retrospective study was conducted using data from Taiwan\u2019s National Health Insurance Research Database. Patients diagnosed with autoimmune diseases between 2000 and 2014, including psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and systemic lupus erythematosus, were included in the study. A control group of patients without autoimmune diseases was selected from the same database during the same period. Patients with autoimmune diseases were divided into two sub-cohorts based on their use of immunosuppressive agents. This study found the risk of fractures was 1.14 times higher in patients with autoimmune diseases than in those without. Moreover, we found that patients in the immunosuppressant sub-cohort had a higher risk of fractures compared to those in the non-immunosuppressant sub-cohort. The adjusted sub-distribution hazard ratio for shoulder fractures was 1.27 (95% CI = 1.01\u20131.58), for spine fractures was 1.43 (95% CI = 1.26\u20131.62), for wrist fractures was 0.95 (95% CI = 0.75\u20131.22), and for hip fractures was 1.67 (95% CI = 1.38\u20132.03). In conclusion, the long-term use of immunosuppressive agents in patients with autoimmune diseases may increase the risk of fractures.<\/jats:p>","DOI":"10.3390\/biomedicines11102764","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T07:28:44Z","timestamp":1697095724000},"page":"2764","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-Term Use of Immunosuppressive Agents Increased the Risk of Fractures in Patients with Autoimmune Diseases: An 18-Year Population-Based Cohort Study"],"prefix":"10.3390","volume":"11","author":[{"given":"Feng-Chen","family":"Kao","sequence":"first","affiliation":[{"name":"Department of Orthopedics, E-Da Hospital, Kaohsiung City 824, Taiwan"},{"name":"School of Medicine, College of Medicine, I-Shou University, Kaohsiung City 824, Taiwan"},{"name":"Department of Orthopedics, E-Da Dachang Hospital, Kaohsiung City 807, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine, I-Shou University, Kaohsiung City 824, Taiwan"},{"name":"Division of Gastroenterology, E-Da Hospital, Kaohsiung City 824, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Kun","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, E-Da Hospital, Kaohsiung City 824, Taiwan"},{"name":"School of Medicine, College of Medicine, I-Shou University, Kaohsiung City 824, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Shan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Research, E-Da Hospital, Kaohsiung City 824, Taiwan"},{"name":"Department of Medical Imaging and Radiological Sciences, College of Medicine, I-Shou University, Kaohsiung City 824, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsi-Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine, I-Shou University, Kaohsiung City 824, Taiwan"},{"name":"Division of Nephrology, Department of Internal Medicine, E-DA Hospital, Kaohsiung City 824, Taiwan"},{"name":"Department of Medical Quality, E-DA Hospital, Kaohsiung City 824, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-6681","authenticated-orcid":false,"given":"Jeff (Chien-Fu)","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Statistics, National Taipei University, Taipei City 23741, Taiwan"},{"name":"Department of Orthopedic Surgery, Wan Fang Hospital, Taipei City 116, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: A comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/rheumatology\/keaa705","article-title":"Fracture risk in systemic lupus erythematosus patients over 28 years","volume":"60","author":"Garelick","year":"2021","journal-title":"Rheumatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00223-017-0322-z","article-title":"Bone Disease in Connective Tissue Disease\/Systemic Lupus Erythematosus","volume":"102","author":"Bultink","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","article-title":"Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis","volume":"54","author":"Geusens","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1080\/14656566.2020.1787381","article-title":"Osteoporosis in patients with rheumatoid arthritis: An update in epidemiology, pathogenesis, and fracture prevention","volume":"21","author":"Raterman","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical Practice. Postmenopausal Osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2018062","DOI":"10.4178\/epih.e2018062","article-title":"Data resource profile: The National Health Insurance Research Database (NHIRD)","volume":"40","author":"Lin","year":"2018","journal-title":"Epidemiol. Health"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pietschmann, P., Butylina, M., Kerschan-Schindl, K., and Sipos, W. (2022). Mechanisms of Systemic Osteoporosis in Rheumatoid Arthritis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158740"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/rheumatology\/kez655","article-title":"The impact of long-term biologics\/target therapy on bone mineral density in rheumatoid arthritis: A propensity score-matched analysis","volume":"59","author":"Chen","year":"2020","journal-title":"Rheumatology"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Li, H.-L., Shen, Y., Tan, L.-H., Fu, S.-B., Dai, R.-C., Yuan, L.-Q., Sheng, Z.-F., Xie, Z.-J., Wu, X.-P., and Liao, E.-Y. (2021). Relationship between bone mineral density and fragility fracture risk: A case-control study in Changsha, China. BMC Musculoskelet. Disord., 22.","DOI":"10.1186\/s12891-021-04616-8"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00296-017-3922-z","article-title":"Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study","volume":"38","author":"Tada","year":"2018","journal-title":"Rheumatol. Int."},{"key":"ref_16","first-page":"102","article-title":"Factors associated with low bone mineral density in female patients with systemic lupus erythematosus","volume":"28","author":"Lakshminarayanan","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1191\/0961203305lu2039oa","article-title":"Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus","volume":"14","author":"Mok","year":"2005","journal-title":"Lupus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00198-012-2157-9","article-title":"Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus","volume":"24","author":"Jacobs","year":"2013","journal-title":"Osteoporos. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3899\/jrheum.131190","article-title":"Bone mineral density change in systemic lupus erythematosus: A 5-year followup study","volume":"41","author":"Zhu","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e10393","DOI":"10.1002\/jbm4.10393","article-title":"The Association of Methotrexate, Sulfasalazine, and Hydroxychloroquine Use with Fracture in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women\u2019s Health Initiative","volume":"4","author":"Carbone","year":"2020","journal-title":"JBMR Plus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"E1440","DOI":"10.1152\/ajpendo.00587.2011","article-title":"Dietary emu oil supplementation suppresses 5-fluorouracil chemotherapy-induced inflammation, osteoclast formation, and bone loss","volume":"302","author":"Nadhanan","year":"2012","journal-title":"Am. J. Physiol. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"18293","DOI":"10.3390\/ijms160818293","article-title":"Potential Effects of Phytoestrogen Genistein in Modulating Acute Methotrexate Chemotherapy-Induced Osteoclastogenesis and Bone Damage in Rats","volume":"16","author":"King","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/annrheumdis-2019-215328","article-title":"Medications associated with fracture risk in patients with rheumatoid arthritis","volume":"78","author":"Ozen","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","first-page":"3416","article-title":"Impact of biologic disease-modifying antirheumatic drugs on fracture risk in patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"25","author":"Shao","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/jbmr.1489","article-title":"Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: A population-based cohort study","volume":"27","author":"Kim","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"106278","DOI":"10.1016\/j.phrs.2022.106278","article-title":"Association between biologic therapy and fracture incidence in patients with selected rheumatic and autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials","volume":"181","author":"Lv","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/acr2.11292","article-title":"Comparative Risk of Nonvertebral Fractures among Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs","volume":"3","author":"Pawar","year":"2021","journal-title":"ACR Open Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00198-020-05488-9","article-title":"Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: A cohort study","volume":"31","author":"Shin","year":"2020","journal-title":"Osteoporos. Int."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/10\/2764\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:05:32Z","timestamp":1760130332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/10\/2764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["biomedicines11102764"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines11102764","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]}}}